{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:16:35Z","timestamp":1783613795563,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer cells avert apoptosis to sustain growth, evade immunity, and resist therapy. However, how they escape specific extrinsic death signals remains unclear. We show that certain epithelial carcinomas co-opt the death-receptor ligand Apo2L\/TRAIL to suppress apoptosis while acquiring killing capacity. Analysis of CRISPR knockout screens from the Cancer Dependency Map uniquely\u00a0identified TRAIL as an essential tumor necrosis factor superfamily member in epithelial malignancies. Renal cell carcinomas (RCC) and squamous cell carcinomas (SCC) expressed TRAIL within both malignant and nonmalignant compartments. In RCC, loss of the tumor suppressor VHL induced HIF2\u03b1-dependent TRAIL transcription, whereas in SCC, 3q26 amplification increased TRAIL abundance. Fractional TRAIL silencing revealed killing of TRAIL-deficient cells by TRAIL-expressing counterparts, while full silencing sensitized cells to extrinsic TRAIL. Mechanistically, endogenous TRAIL suppressed apoptosis through lysosomal degradation of its cognate death receptors. Thus, cancer cells can repurpose TRAIL via a surprising apoptotic \u201ccloak-and-dagger\u201d mechanism with significant therapeutic potential.<\/jats:p>","DOI":"10.1038\/s41418-026-01798-3","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:32:12Z","timestamp":1783607532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epithelial cancer cells co-opt the death ligand TRAIL to avert extrinsic apoptosis while acquiring killing capacity"],"prefix":"10.1038","author":[{"given":"John","family":"Canty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot","family":"Marsters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Koeppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6890-4589","authenticated-orcid":false,"given":"Avi","family":"Ashkenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"1798_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1798_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","volume":"116","author":"NN Danial","year":"2004","unstructured":"Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116:205\u201319.","journal-title":"Cell"},{"key":"1798_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27\u201336.","journal-title":"Cell Death Differ"},{"key":"1798_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd.2016.253","volume":"16","author":"A Ashkenazi","year":"2017","unstructured":"Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16:273\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"1798_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nrc821","volume":"2","author":"A Ashkenazi","year":"2002","unstructured":"Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420\u2013430.","journal-title":"Nat Rev Cancer"},{"key":"1798_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"1798_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc.2017.28","volume":"17","author":"S Von Karstedt","year":"2017","unstructured":"Von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17:352\u2013366.","journal-title":"Nat Rev Cancer"},{"key":"1798_CR8","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687\u201390.","journal-title":"J Biol Chem"},{"key":"1798_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C-P, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673\u201382.","journal-title":"Immunity"},{"key":"1798_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1172\/JCI6926","volume":"104","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig. 1999;104:155\u201362.","journal-title":"J Clin Investig"},{"key":"1798_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor\u2013related apoptosis\u2013inducing ligand in vivo. Nat Med. 1999;5:157\u201363.","journal-title":"Nat Med"},{"key":"1798_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","volume":"281","author":"A Ashkenazi","year":"1998","unstructured":"Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305\u201308.","journal-title":"Science"},{"key":"1798_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1074-7613(00)80212-5","volume":"12","author":"FC Kischkel","year":"2000","unstructured":"Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L\/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12:611\u201320.","journal-title":"Immunity"},{"key":"1798_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1074-7613(00)80211-3","volume":"12","author":"MR Sprick","year":"2000","unstructured":"Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12:599\u2013609.","journal-title":"Immunity"},{"key":"1798_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/cells13060521","volume":"13","author":"A Guerrache","year":"2024","unstructured":"Guerrache A, Micheau O. TNF-related apoptosis-inducing ligand: non-apoptotic signalling. Cells. 2024;13:521.","journal-title":"Cells"},{"key":"1798_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2637","volume":"7","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7:1001\u201312.","journal-title":"Nat Rev Drug Discov"},{"key":"1798_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1172\/JCI80420","volume":"125","author":"A Ashkenazi","year":"2015","unstructured":"Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: Lessons learned and future directions. J Clin Investig. 2015;125:487\u20139.","journal-title":"J Clin Investig"},{"key":"1798_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, Von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014;21:1350\u201364.","journal-title":"Cell Death Differ"},{"key":"1798_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/BST20220098","volume":"51","author":"F Di Cristofano","year":"2023","unstructured":"Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, et al. Therapeutic targeting of TRAIL death receptors. Biochem Soc Trans. 2023;51:57\u201370.","journal-title":"Biochem Soc Trans"},{"key":"1798_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","volume":"30","author":"A Montinaro","year":"2023","unstructured":"Montinaro A, Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ. 2023;30:237\u201349.","journal-title":"Cell Death Differ"},{"key":"1798_CR21","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1073\/pnas.1418962112","volume":"112","author":"PM Nair","year":"2015","unstructured":"Nair PM, Flores H, Gogineni A, Marsters S, Lawrence DA, Kelley RF, et al. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc Natl Acad Sci USA. 2015;112:5679\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1798_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1535-7163.MCT-15-0647","volume":"15","author":"P Br\u00fcnker","year":"2016","unstructured":"Br\u00fcnker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, et al. RG7386, a novel tetravalent FAP-DR5 antibody, effectively triggers FAP-dependent, avidity-driven DR5 hyperclustering and tumor cell apoptosis. Mol Cancer Ther. 2016;15:946\u201357.","journal-title":"Mol Cancer Ther"},{"key":"1798_CR23","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, et al. Preclinical characterization and phase I trial results of INBRX-109, a third-generation, recombinant, humanized, death receptor 5 agonist antibody, in chondrosarcoma. Clin Cancer Res. 2023;29:2988\u20133003.","journal-title":"Clin Cancer Res"},{"key":"1798_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-024-02004-9","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Aponermin: first approval. Drugs. 2024;84:459\u2013466.","journal-title":"Drugs"},{"key":"1798_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10555-024-10206-6","volume":"43","author":"O Ababneh","year":"2024","unstructured":"Ababneh O, Nishizaki D, Kato S, Kurzrock R. Tumor necrosis factor superfamily signaling: Life and death in cancer. Cancer Metastasis Rev. 2024;43:1137\u201363.","journal-title":"Cancer Metastasis Rev"},{"key":"1798_CR26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nm1627","volume":"13","author":"KW Wagner","year":"2007","unstructured":"Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L\/TRAIL. Nat Med. 2007;13:1070\u20137.","journal-title":"Nat Med"},{"key":"1798_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccr.2010.11.012","volume":"19","author":"NS Wilson","year":"2011","unstructured":"Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fc\u03b3 receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 2011;19:101\u201313.","journal-title":"Cancer Cell"},{"key":"1798_CR28","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s43018-023-00571-6","volume":"4","author":"H Kalkavan","year":"2023","unstructured":"Kalkavan H, R\u00fchl S, Shaw JJP, Green DR. Non-lethal outcomes of engaging regulated cell death pathways in cancer. Nat Cancer. 2023;4:795\u2013806.","journal-title":"Nat Cancer"},{"key":"1798_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1172\/JCI33061","volume":"118","author":"A Grosse-Wilde","year":"2008","unstructured":"Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Investig. 2008;118:100\u201310.","journal-title":"J Clin Investig"},{"key":"1798_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.molcel.2017.01.021","volume":"65","author":"T Hartwig","year":"2017","unstructured":"Hartwig T, Montinaro A, Von Karstedt S, Sevko A, Surinova S, Chakravarthy A, et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol Cell. 2017;65:730\u2013742.e5.","journal-title":"Mol Cell"},{"key":"1798_CR31","doi-asserted-by":"publisher","first-page":"7434","DOI":"10.1038\/sj.onc.1209719","volume":"25","author":"A Trauzold","year":"2006","unstructured":"Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006;25:7434\u20139.","journal-title":"Oncogene"},{"key":"1798_CR32","doi-asserted-by":"publisher","first-page":"40599","DOI":"10.1074\/jbc.M509560200","volume":"280","author":"E Varfolomeev","year":"2005","unstructured":"Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, et al. Molecular determinants of kinase pathway activation by Apo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005;280:40599\u2013608.","journal-title":"J Biol Chem"},{"key":"1798_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccell.2015.02.014","volume":"27","author":"S von\u00a0Karstedt","year":"2015","unstructured":"von\u00a0Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell. 2015;27:561\u201373.","journal-title":"Cancer Cell"},{"key":"1798_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/sj.cdd.4401523","volume":"12","author":"HH Yue","year":"2005","unstructured":"Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ. 2005;12:94\u201397.","journal-title":"Cell Death Differ"},{"key":"1798_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","volume":"104","author":"RM Locksley","year":"2001","unstructured":"Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies. Cell. 2001;104:487\u2013501.","journal-title":"Cell"},{"key":"1798_CR36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564\u2013576.e16.","journal-title":"Cell"},{"key":"1798_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cellimm.2010.02.003","volume":"262","author":"B Berent-Maoz","year":"2010","unstructured":"Berent-Maoz B, Salemi S, Mankuta D, Simon H-U, Levi-Schaffer F. Human mast cells express intracellular TRAIL. Cell Immunol. 2010;262:80\u20133.","journal-title":"Cell Immunol"},{"key":"1798_CR38","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1084\/jem.189.8.1343","volume":"189","author":"TS Griffith","year":"1999","unstructured":"Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor\u2013related cytokine, TRAIL. J Exp Med. 1999;189:1343\u201354.","journal-title":"J Exp Med"},{"key":"1798_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add5028","volume":"9","author":"C Riera-Domingo","year":"2023","unstructured":"Riera-Domingo C, Leite-Gomes E, Charatsidou I, Zhao P, Carr\u00e1 G, Cappellesso F, et al. Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding. Sci Adv. 2023;9:eadd5028.","journal-title":"Sci Adv"},{"key":"1798_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin","year":"2008","unstructured":"Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393\u2013402.","journal-title":"Mol Cell"},{"key":"1798_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jbior.2015.10.009","volume":"60","author":"AP Fields","year":"2016","unstructured":"Fields AP, Justilien V, Murray NR. The chromosome 3q26 OncCassette: a multigenic driver of human cancer. Adv Biol Regul. 2016;60:47\u201363.","journal-title":"Adv Biol Regul"},{"key":"1798_CR42","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/ng.465","volume":"41","author":"AJ Bass","year":"2009","unstructured":"Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238\u201342.","journal-title":"Nat Genet"},{"key":"1798_CR43","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/362462a0","volume":"362","author":"T Miki","year":"1993","unstructured":"Miki T, Smith CL, Long JE, Eva A, Fleming TP. Oncogene ect2 is related to regulators of small GTP-binding proteins. Nature. 1993;362:462\u20135.","journal-title":"Nature"},{"key":"1798_CR44","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1158\/0008-5472.CAN-07-5084","volume":"68","author":"H Yamamoto","year":"2008","unstructured":"Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008;68:6913\u201321.","journal-title":"Cancer Res"},{"key":"1798_CR45","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood.V90.3.1168","volume":"90","author":"O Monni","year":"1997","unstructured":"Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood. 1997;90:1168\u201374.","journal-title":"Blood"},{"key":"1798_CR46","doi-asserted-by":"publisher","first-page":"12492","DOI":"10.1073\/pnas.1507491112","volume":"112","author":"H Park","year":"2015","unstructured":"Park H, Cho S-Y, Kim H, Na D, Han JY, Chae J, et al. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc Natl Acad Sci USA. 2015;112:12492\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1798_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: Current status and perspectives. J Hematol Oncol. 2021;14:67.","journal-title":"J Hematol Oncol"},{"key":"1798_CR48","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1074\/jbc.M410660200","volume":"280","author":"RF Kelley","year":"2005","unstructured":"Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, DeForge L, et al. Receptor-selective mutants of apoptosis-inducing ligand 2\/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005;280:2205\u201312.","journal-title":"J Biol Chem"},{"key":"1798_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ng1097-141","volume":"17","author":"GS Wu","year":"1997","unstructured":"Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, et al. KILLER\/DR5 is a DNA damage\u2013inducible p53\u2013regulated death receptor gene. Nat Genet. 1997;17:141\u20133.","journal-title":"Nat Genet"},{"key":"1798_CR50","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/25387","volume":"396","author":"RM Pitti","year":"1998","unstructured":"Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699\u2013703.","journal-title":"Nature"},{"key":"1798_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2008.11.023","volume":"281","author":"S Fulda","year":"2009","unstructured":"Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett. 2009;281:128\u201333.","journal-title":"Cancer Lett"},{"key":"1798_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48\u201361.","journal-title":"Cell"},{"key":"1798_CR53","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41419-021-04066-z","volume":"12","author":"Z Cui","year":"2021","unstructured":"Cui Z, Dabas H, Leonard BC, Shiah JV, Grandis JR, Johnson DE. Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. Cell Death Dis. 2021;12:775.","journal-title":"Cell Death Dis"},{"key":"1798_CR54","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.canlet.2010.10.009","volume":"332","author":"S Shirley","year":"2013","unstructured":"Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett. 2013;332:141\u2013150.","journal-title":"Cancer Lett"},{"key":"1798_CR55","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2023.12.016","volume":"42","author":"C Pacini","year":"2024","unstructured":"Pacini C, Duncan E, Gon\u00e7alves E, Gilbert J, Bhosle S, Horswell S, et al. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. Cancer Cell. 2024;42:301\u2013316.e9.","journal-title":"Cancer Cell"},{"key":"1798_CR56","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1126\/science.270.5239.1189","volume":"270","author":"TS Griffith","year":"1995","unstructured":"Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189\u201392.","journal-title":"Science"},{"key":"1798_CR57","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jcmgh.2024.01.006","volume":"17","author":"EJ Loeuillard","year":"2024","unstructured":"Loeuillard EJ, Li B, Stumpf HE, Yang J, Willhite JR, Tomlinson JL, et al. Noncanonical TRAIL signaling promotes myeloid-derived suppressor cell abundance and tumor growth in cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2024;17:853\u201376.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1798_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113476","volume":"42","author":"P Davidovich","year":"2023","unstructured":"Davidovich P, Higgins CA, Najda Z, Longley DB, Martin SJ. cFLIPL acts as a suppressor of TRAIL- and Fas-initiated inflammation by inhibiting assembly of caspase-8\/FADD\/RIPK1 NF-\u03baB-activating complexes. Cell Rep. 2023;42:113476.","journal-title":"Cell Rep"},{"key":"1798_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg2829","volume":"9","author":"K Martinez Lagunas","year":"2023","unstructured":"Martinez Lagunas K, Savcigil DP, Zrilic M, Carvajal Fraile C, Craxton A, Self E, et al. Cleavage of cFLIP restrains cell death during viral infection and tissue injury and favors tissue repair. Sci Adv. 2023;9:eadg2829.","journal-title":"Sci Adv"},{"key":"1798_CR60","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1200\/JCO.2011.37.2623","volume":"29","author":"J-C Soria","year":"2011","unstructured":"Soria J-C, M\u00e1rk Z, Zatloukal P, Szima B, Albert I, Juh\u00e1sz E, et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non\u2013small-cell lung cancer. J Clin Oncol. 2011;29:4442\u201351.","journal-title":"J Clin Oncol"},{"key":"1798_CR61","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10:552\u201367.","journal-title":"Cancer Discov"},{"key":"1798_CR62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/cdd.2013.179","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, Von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A, et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ. 2014;21:491\u2013502.","journal-title":"Cell Death Differ"},{"key":"1798_CR63","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1158\/1535-7163.MCT-17-0121","volume":"16","author":"MD Ralff","year":"2017","unstructured":"Ralff MD, Kline CLB, K\u00fc\u00e7\u00fckkase OC, Wagner J, Lim B, Dicker DT, et al. ONC201 demonstrates antitumor effects in both triple-negative and non\u2013triple-negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. Mol Cancer Ther. 2017;16:1290\u201398.","journal-title":"Mol Cancer Ther"},{"key":"1798_CR64","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s43018-022-00462-2","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang L, Jin H, Jochems F, Wang S, Lieftink C, Martinez IM, et al. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nat Cancer. 2022;3:1284\u201399.","journal-title":"Nat Cancer"},{"key":"1798_CR65","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41586-025-08997-x","volume":"643","author":"C Faust Akl","year":"2025","unstructured":"Faust Akl C, Andersen BM, Li Z, Giovannoni F, Diebold M, Sanmarco LM, et al. Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025;643:219\u201329.","journal-title":"Nature"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01798-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01798-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:02:31Z","timestamp":1783612951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01798-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":65,"alternative-id":["1798"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01798-3","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. All authors were paid\u00a0employees of Genentech, Inc. at the time of this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}